Table 2: Current experience with iVAC2L device.

Author, Year

#N, pts

Age (years)

Device

Access

Indication

Pre-IVAC

Post-IVAC

Complications*

Vascular- site complications**

Survival n/N

MAP (mmHg)

PCWP (mmHg)

CI (L/min/m2)

MAP (mmHg)

PCWP (mmHg)

CI (L/min/m2)

Tschope, 2020 [22]

1

49

iVAC2L & VA ECMO

Femoral Artery

CS

N/A

N/A

N/A

N/A

N/A

N/A

N/A

No

1/1

Tzikas, 2020 [43]

1

46

iVAC2L

Femoral Artery

CS

38

22

1.2

60

32

2.5

No

No

0/1

Samol, 2019 [42,44]

17

72 ± 9

iVAC2L

Femoral Artery

High-riskPCI

81 ± 17

N/A

N/A

81 ± 17

N/A

N/A

1

1

17/17

Bastos, 2018 [45]

1

70

iVAC2L

Femoral Artery

High-risk PCI

N/A

N/A

1.27 (CO)

N/A

N/A

1.29 (CO)

No

No

1/1

Den Uil, 2017 [46]

14

72 ± 8

iVAC2L

Femoral Artery

High-risk PCI

66.5 ± 8.7

13.1 ± 6.4

2.2 ± 0.7

84.9 ± 9

11.2 ± 4.8

2.8 ± 0.8

2

No

13/13 ***

Arrigoni, 2011 [12]

1

76

iVAC3L

Pulmonary Artery Trunk to RV

RV support in CS & IABP

45

N/A

2.88 (CO)

75

ΝΑ

3.3 (CO)

1

No

0/1

1

73

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

1/1

Anastasiadis, 2011 [21]

1

33

iVAC3L & VA ECMO

Axillart Artery

LV support due to ECMO use

N/A

N/A

N/A

N/A

N/A

N/A

No

No

1/1

Amico, 2008 [47]

1

76

iVAC3L

Aorta

LV support during CABG

74

N/A

N/A

83

N/A

N/A

No

No

1/1

Marianni, 2007 [48]

14

69 ± 7

iVAC3L

Aorta

LV support during CABG

N/A

N/A

N/A

N/A

N/A

N/A

No

No

14/14

N: Number; pts: patients; N/A: not available; MAP: Mean Arterial Pressure; PCWP: Pulmonary Capillary Wedge Pressure; CI: Cardiac Index; CO: Cardiac Output; CS: Cardiogenic Shock; PCI: Percutaneous Coronary Intervention; LV: Left Ventricle; RV: Right Ventricle; CABG: Coronary Artrery Bypass Graft; VAECMO: Venous - Arterial Extracorporeal Membrane Oxygenation; IABP: Intra-Aortic Balloon Pump

*: any adverse event (acute kidney injury, stroke andtransient ischemic attack)

**: vascular bleeding, puncture site infection or swelling

***: one patient was excluded from post-procedural analyses